Methods for treating disorders associated with hyperlipidemia in a mammal
First Claim
1. A method of reducing at least one of (i) the concentration of cholesterol and/or triglycerides in the blood of a mammal, and (ii) the amount of a marker of atherosclerosis in a mammal, the method comprising administering each day to the mammal a combination of ezetimibe and BMS-201038, wherein BMS 201038 initially is administered at a first dosage in the range of 2.5 to 7.5 mg/day for at least 4 weeks, is then administered at a second dosage in the range of 5 to 10 mg/day for at least 4 weeks, and is then administered at a third dosage in the range of 7.5 to 12.5 mg/day for at least 4 weeks.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit.
-
Citations
41 Claims
- 1. A method of reducing at least one of (i) the concentration of cholesterol and/or triglycerides in the blood of a mammal, and (ii) the amount of a marker of atherosclerosis in a mammal, the method comprising administering each day to the mammal a combination of ezetimibe and BMS-201038, wherein BMS 201038 initially is administered at a first dosage in the range of 2.5 to 7.5 mg/day for at least 4 weeks, is then administered at a second dosage in the range of 5 to 10 mg/day for at least 4 weeks, and is then administered at a third dosage in the range of 7.5 to 12.5 mg/day for at least 4 weeks.
- 18. A method of reducing hepatic steatosis in a patient receiving BMS-201038, the method comprising co-administering BMS-201038 and ezetimibe to the patient.
- 24. A method of reducing at least one of (i) the concentration of cholesterol and/or triglycerides in the blood of a mammal, and (ii) the amount of a marker of atherosclerosis in a mammal, the method comprising administering each clay to the mammal a combination of ezetimibe and implitapide, wherein the implitapide is administered at a dosage in the range of 0.01 to 60 mg/day.
- 38. A method of lowering the concentration of cholesterol and/or triglycerides in the blood of a mammal, the method comprising administering implitapide at a dosage of about 10 to 60 mg/day so as to reduce the concentration of the cholesterol and/or the triglycerides.
Specification